hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
Table 1
Clinical characteristics of 493 PTC patients from TCGA-THCA database, stratified by disease stages (stage I_II vs. stage III_IV).
Characteristics
Total
Stage I_II
Stage III_IV
value
No.
493
328
165
Gender (%)
Female
360 (73.02)
249 (75.91)
111 (67.27)
0.0533
Male
133 (26.98)
79 (24.09)
54 (32.73)
Age (%)
<60
382 (77.48)
284 (86.59)
98 (59.39)
<0.0001
>60
111 (22.52)
44 (13.41)
67 (40.61)
Radiation therapy (%)
No
178 (36.10)
143 (43.60)
35 (21.21)
<0.0001
Yes
315 (63.89)
185 (56.40)
130 (78.79)
Neoadjuvant therapy (%)
No
489 (99.19)
326 (99.39)
163 (98.79)
0.8638
Yes
4 (0.81)
2 (0.61)
2 (1.21)
Survival status (%)
Alive
477 (96.75)
324 (98.78)
153 (92.73)
0.0009
Dead
16 (3.25)
4 (1.22)
12 (7.27)
Patients of stage I and stage II were categorized as the stage I_II group, and patients of stage III and IV were categorized as the stage III_IV group. value is derived from the univariate association analyses between each of the clinicopathologic variables and stage status. value < 0.05 and value < 0.001.
